- Home
- BMRN vs DKNG Comparison
BMRN vs DKNG Comparison
Compare BMRN & DKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | DKNG |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 13.0B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BMRN | DKNG |
|---|---|---|
| Price | $66.53 | $24.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 31 |
| Target Price | ★ $88.22 | $38.10 |
| AVG Volume (30 Days) | 2.2M | ★ 11.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.05 |
| EPS | ★ 0.77 | N/A |
| Revenue | $1,313,646,000.00 | ★ $6,054,525,000.00 |
| Revenue This Year | $15.02 | $15.47 |
| Revenue Next Year | $12.23 | $13.09 |
| P/E Ratio | $86.55 | ★ N/A |
| Revenue Growth | 17.62 | ★ 26.99 |
| 52 Week Low | $49.26 | $20.46 |
| 52 Week High | $70.98 | $46.79 |
Technical Indicators
Market Signals| Indicator | BMRN | DKNG |
|---|---|---|
| Relative Strength Index (RSI) | 56.83 | 48.83 |
| Support Level | $58.03 | $23.74 |
| Resistance Level | $70.98 | $26.82 |
| Average True Range (ATR) | 1.56 | 1.18 |
| MACD | -0.34 | -0.11 |
| Stochastic Oscillator | 46.31 | 34.97 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. With its predictive market launch in 2025, DraftKings is now live with online or retail sports betting in most all states and i-gaming in five states, with both products available to about 50% of Canada's population. In 2025, sports revenue was 63% of total sales, i-gaming 30%, and fantasy and lottery 7%.